Free Trial
NYSE:COR

Cencora (COR) Stock Price, News & Analysis

$227.57
+0.46 (+0.20%)
(As of 07/26/2024 ET)
Today's Range
$226.47
$228.94
50-Day Range
$216.21
$239.32
52-Week Range
$171.65
$246.75
Volume
1.31 million shs
Average Volume
1.36 million shs
Market Capitalization
$45.39 billion
P/E Ratio
24.90
Dividend Yield
0.90%
Price Target
$238.78

Cencora MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
4.9% Upside
$238.78 Price Target
Short Interest
Healthy
4.76% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.77
Upright™ Environmental Score
News Sentiment
0.50mentions of Cencora in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$408.65 M Sold Last Quarter
Proj. Earnings Growth
9.73%
From $13.46 to $14.77 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.53 out of 5 stars

Medical Sector

100th out of 936 stocks

Drugs, Proprietaries, & Sundries Industry

3rd out of 6 stocks

COR stock logo

About Cencora Stock (NYSE:COR)

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

COR Stock Price History

COR Stock News Headlines

Musk’s new company could top a trillion?
The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.
Cencora, Inc. (NYSE:COR) Receives $238.78 Average PT from Brokerages
Evercore ISI Keeps Their Buy Rating on Cencora (COR)
Musk’s new company could top a trillion?
The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.
COR Aug 2024 170.000 put
See More Headlines
Receive COR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cencora and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/01/2024
Ex-Dividend for 5/24 Dividend
5/09/2024
Dividend Payable
5/24/2024
Today
7/26/2024
Next Earnings (Confirmed)
7/31/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drugs, proprietaries, & sundries
Sub-Industry
Health Care Distributors
CUSIP
03073E10
Employees
46,000
Year Founded
2001

Price Target and Rating

Average Stock Price Target
$238.78
High Stock Price Target
$285.00
Low Stock Price Target
$190.00
Potential Upside/Downside
+4.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$1.75 billion
Pretax Margin
0.83%

Debt

Sales & Book Value

Annual Sales
$262.17 billion
Cash Flow
$17.21 per share
Book Value
$3.32 per share

Miscellaneous

Free Float
167,939,000
Market Cap
$45.39 billion
Optionable
Optionable
Beta
0.45

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Should I Buy Cencora Stock? COR Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Cencora, Inc.:

  • Cencora, Inc. reported strong quarterly earnings results, beating analysts' consensus estimates by $0.15 per share, indicating solid financial performance.
  • The company has a healthy dividend payout ratio of 22.32%, offering investors a steady income stream through dividends.
  • Wall Street analysts have given Cencora, Inc. a positive outlook with an average rating of "Moderate Buy" and a consensus target price of $235.30, suggesting potential for stock price appreciation.
  • Cencora, Inc. has a market capitalization of $44.41 billion, indicating the company's size and stability in the market.
  • The stock price of Cencora, Inc. has shown resilience, trading up 0.1% recently, demonstrating investor confidence in the company.

Cons

Investors should be bearish about investing in Cencora, Inc. for these reasons:

  • Cencora, Inc. has a debt-to-equity ratio of 3.41, which may indicate higher financial leverage and potential risk for investors.
  • The company's net margin is relatively low at 0.67%, suggesting lower profitability compared to industry peers.
  • While revenue was up 7.8% year-over-year, it fell short of analysts' expectations, indicating potential challenges in revenue growth.
  • The company's quick ratio of 0.53 may raise concerns about its short-term liquidity and ability to meet immediate financial obligations.
  • Despite positive analyst ratings, there are three hold ratings on the stock, signaling some uncertainty in the market about Cencora, Inc.'s future performance.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, July 23, 2024. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

COR Stock Analysis - Frequently Asked Questions

How have COR shares performed this year?

Cencora's stock was trading at $205.38 on January 1st, 2024. Since then, COR stock has increased by 10.8% and is now trading at $227.57.
View the best growth stocks for 2024 here
.

How were Cencora's earnings last quarter?

Cencora, Inc. (NYSE:COR) posted its quarterly earnings results on Wednesday, May, 1st. The company reported $3.80 EPS for the quarter, beating the consensus estimate of $3.65 by $0.15. The business's revenue was up 7.8% compared to the same quarter last year.

What is Paul E. Szurek's approval rating as Cencora's CEO?

27 employees have rated Cencora Chief Executive Officer Paul E. Szurek on Glassdoor.com. Paul E. Szurek has an approval rating of 86% among the company's employees.

Does Cencora have any subsidiaries?

Cencora subsidiaries include these companies: Alliance Healthcare, H. D. Smith, St. Francis Group, PharMEDium Healthcare, MWI Veterinary Supply, World Courier, IntrinsiQ, and others.

Who are Cencora's major shareholders?

Top institutional shareholders of Cencora include Swedbank AB (0.68%), Bank of New York Mellon Corp (0.60%), Sumitomo Mitsui Trust Holdings Inc. (0.49%) and Wealth Enhancement Advisory Services LLC (0.13%). Insiders that own company stock include Walgreens Boots Alliance, Inc, Steven H Collis, John G Chou, Robert P Mauch, Robert P Mauch, Dermot Mark Durcan, Lazarus Krikorian, Gina Clark, Gina Clark, Leslie E Donato, Leslie E Donato, Elizabeth S Campbell and Silvana Battaglia.
View institutional ownership trends
.

How do I buy shares of Cencora?

Shares of COR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Cencora own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cencora investors own include Digital Realty Trust (DLR), NVIDIA (NVDA), Cisco Systems (CSCO), AbbVie (ABBV), Crown Castle (CCI), AT&T (T) and Intel (INTC).

This page (NYSE:COR) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners